Pluripotent stem cells are a class of pluripotent cells with the ability to self-renew indefinitely in vitro and differentiate into various cell types in the body. They are important tools for studying gene function, building disease models and advancing the field of regenerative medicine.
The pluripotency of stem cells is regulated and maintained by transcriptional networks that include a series of pluripotent transcription factors. These pluripotent genes stimulate or inhibit the expression of downstream genes, inducing the occurrence of some signaling pathways and regulating the pluripotency of stem cells.
Stem cells retain the potential for self-renewal and multidirectional differentiation in the action of signaling pathways regulating the pluripotency of stem cells. Having a better understanding of the mechanism of these pathways could help scientists study gene function ＆ disease pathogenesis and promote the development of regenerative medicine.
Human pluripotent stem cells (hPSCs) are originally established on the feeder layer, murine embryo fibroblast (MEF) irradiated or treated with mitomycin. The feeder layer not only provides nutrition for cell growth but also secrets cytokines (Activin A, IGF-2) that synergize with bFGF (basic fibroblast growth factor) in the culture solution to maintain the pluripotency of human stem cells.
Low concentrations of bFGF can maintain the pluripotency of hPSC in the presence of feeder cells. Because the insulin-like growth factor (IGF) induced by bFGF activates the PI3K-AKT signaling pathway, which inhibits the expression of GSK3, inhibiting the degradation of β-Catenin and maintaining the pluripotency of hPSCs.
Besides, Activin/Nodal/TGF-β respectively binds to their receptors on the cell membrane in the presence of bFGF, activating intracellular cytoplasmic SMAD2/SMAD3. Active SMAD2/3 and SMAD4 form heterodimers into the nucleus, regulating the expression of related genes that maintain the pluripotency of hPSCs. SMAD2/3 can be directly conjugated to the proximal promoter region of Nanog to upregulate the expression of this gene. When the expression of Nanog is increased, the expression of SMAD2/3 is inhibited by negative feedback regulation, and Activin/Nodal/TGF-β signaling pathway in hPSC is controlled to ensure that hPSCs cannot be induced to differentiate into mesendoderm.
BMP4 (bone morphognic protein 4) binds to BMPR, phosphorylating cellular SMAD1, SMAD5, and SMAD8 rather than SMAD2/3. Phosphorylated SMAD1/5/8 further binds to SMAD4 and enters into the nucleus to modulate transcription. When BMP4 in the culture solution is not enough to maintain hPSC self-renewing, the BMP4-SMAD1/5/8 signaling upregulates with the differentiation of hPSCs.
|DVL2||DVL2 Antibody||DVL2 Protein||DVL2 cDNA||DVL2 ELISA Kit|
|DVL3||DVL3 Antibody||DVL3 Protein||DVL3 cDNA||DVL3 ELISA Kit|
|ESRRB||ESRRB Antibody||ESRRB Protein||ESRRB cDNA||ESRRB ELISA Kit|
|ESX1||ESX1 Antibody||ESX1 Protein||ESX1 cDNA||ESX1 ELISA Kit|
|FGF2||FGF2 Antibody||FGF2 Protein||FGF2 cDNA||FGF2 ELISA Kit|
|FGFR1||FGFR1 Antibody||FGFR1 Protein||FGFR1 cDNA||FGFR1 ELISA Kit|
|FGFR2||FGFR2 Antibody||FGFR2 Protein||FGFR2 cDNA||FGFR2 ELISA Kit|
|FGFR3||FGFR3 Antibody||FGFR3 Protein||FGFR3 cDNA||FGFR3 ELISA Kit|
|FGFR4||FGFR4 Antibody||FGFR4 Protein||FGFR4 cDNA||FGFR4 ELISA Kit|
|FZD1||FZD1 Antibody||FZD1 Protein||FZD1 cDNA||FZD1 ELISA Kit|
|FZD10||FZD10 Antibody||FZD10 Protein||FZD10 cDNA||FZD10 ELISA Kit|
|FZD2||FZD2 Antibody||FZD2 Protein||FZD2 cDNA||FZD2 ELISA Kit|
|FZD3||FZD3 Antibody||FZD3 Protein||FZD3 cDNA||FZD3 ELISA Kit|
|FZD4||FZD4 Antibody||FZD4 Protein||FZD4 cDNA||FZD4 ELISA Kit|
|FZD5||FZD5 Antibody||FZD5 Protein||FZD5 cDNA||FZD5 ELISA Kit|
|FZD6||FZD6 Antibody||FZD6 Protein||FZD6 cDNA||FZD6 ELISA Kit|
|FZD7||FZD7 Antibody||FZD7 Protein||FZD7 cDNA||FZD7 ELISA Kit|
|FZD8||FZD8 Antibody||FZD8 Protein||FZD8 cDNA||FZD8 ELISA Kit|
|FZD9||FZD9 Antibody||FZD9 Protein||FZD9 cDNA||FZD9 ELISA Kit|
|GRB2||GRB2 Antibody||GRB2 Protein||GRB2 cDNA||GRB2 ELISA Kit|